Angiogenesis
FDA Approves Avastin for the Most Common Type of Kidney Cancer
Published in Drug Law Weekly, August 18th, 2009
Genentech, Inc., a wholly-owned member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) approved Avastin (bevacizumab) plus interferon-alfa for people with metastatic renal cell carcinoma, the most common type of kidney cancer. According to the American Cancer Society, kidney cancer is the eighth most commonly diagnosed cancer in the United States. In 2009, approximately 13,000 Americans will die from the disease.
"During the last five years, Avastin has been approved by the FDA to treat five different types of cancer," said Hal Barron, M.D., executive vice president, Global Development and chief medical officer, Genentech. "We aim to help...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2009-08-18)
More Articles from Drug Law Weekly
- AARP New York
AARP Responds to Health Reform Scare Tactics - Autoimmune Disease
AutoImmune Inc. Reports 2009 Second Quarter Financial Results - BELL
BELL Summer Challenge Seeks 10,000 Signatures to Help Raise Books for Children in Under-Resourced Communities - Biopharmaceuticals
Research findings from H. Horikawa et al update understanding of biopharmaceuticals - Clinical Trial Research
New clinical trial research study findings recently were reported by researchers at Nancy University - Defibrillators
Senate Hearing Highlights Victim's Medical Device Nightmare, Asks Congress to Hold Manufacturer Accountable - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
